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Sir
Iacopetta et al (2001) recently reported on a study investigating
colorectal cancer patient survival among patients with different
genotypes in the thymidylate synthase promoter region, undergoing
either surgery alone or treatment with 5-ﬂuorouracil (5-FU). The
authors stated that ‘patients with the 3R/3R polymorphism showed
no signiﬁcant long-term survival beneﬁt from chemotherapy
(RR=0.62, 95% CI 0.30–1.25, P=0.18) (n=48), whereas those with
the 2R/2R or 2R/3R genotype showed signiﬁcant gains in survival
(RR=0.52, 95% CI 0.52–0.82, P=0.005)’. Thus, the authors imply
that the 38% survival beneﬁt among patients with the 3R/3R geno-
type is different from the 48% survival beneﬁt seen among patients
with the 2R/2R or 2R/3R genotype. This conclusion is inappropri-
ate: there was no statistical test performed to compare the 38%
survival beneﬁt to the 48% survival beneﬁt, and the difference
would clearly not be statistically signiﬁcant. The fact that, in, Table
3, the 3R/3R patients do not show statistically signiﬁcant survival
from surgery alone, whereas the other TS genotypes do, is not
the relevant question.
We are concerned that the presentation and interpretation of
the study results are misleading. The authors stated: ‘These results
demonstrate that a polymorphism within the TS gene, can inﬂu-
ence the survival beneﬁt obtained by colorectal cancer patients
from 5-FU-based chemotherapy’. There was no association
between the TS polymorphism and overall survival, or survival
among patients who received chemotherapy (which would be
the most logical research question to investigate, given that the
TS polymorphism should be relevant only among patients receiv-
ing antifolate chemotherapeutic agents). Further, there is no
signiﬁcant difference in the association between chemotherapy
and patient survival that differs by genotype – the beneﬁts in
both groups are in the range of 40–50%. The authors have used
less than optimal methods to study the research question of
interest.
The question of whether thymidylate synthase polymorphisms
alter the effectiveness and toxicity of treatment with 5-FU is an
important one that still requires a carefully conducted study.
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